{
    "clinical_study": {
        "@rank": "62166", 
        "acronym": "HMPL-504", 
        "arm_group": [
            {
                "arm_group_label": "Volitinib ,after high fat meal intake ,capsule", 
                "arm_group_type": "Experimental", 
                "description": "A:single oral Volitinib  after high fat meal intake"
            }, 
            {
                "arm_group_label": "Volitinib,after general diet,capsule", 
                "arm_group_type": "Experimental", 
                "description": "B:single oral Volitinib, after general diet"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate to determine the effect of food on the PK of a\n      single dose of 600 mg Volitinib and its two major metabolites in healthy subjects."
        }, 
        "brief_title": "A Food Effect Phase I Study of the Volitinib in Healthy Subjects", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Food Effect", 
            "Health Subjects"
        ], 
        "detailed_description": {
            "textblock": "The purpose of this study is to evaluate to determine the effect of food on the PK(\n      pharmacokinetics) of a single dose of 600 mg Volitinib and its two major metabolites in\n      healthy subjects and to assess the safety and tolerability of single doses of 600mg in\n      healthy subjects.This study will be an open-label, randomized, four-period, crossover PK\n      food effect study of Volitinib administered orally at 600 mg. Subjects will be screened for\n      eligibility up to 14 days prior to entry into the study,there will be 4 treatments,2 weeks\n      follow-up."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males , between 18 and 45 years of age, inclusive.\n\n          -  Body mass index (BMI) within the range of 19 to 25 kg/m2, inclusive.\n\n          -  In good health, determined by no clinically significant findings from medical\n             history, physical examination, 12-lead ECG, and vital signs.\n\n          -  Adequate hepatic, renal, heart, and hematologic functions\n\n          -  Male subjects who are either sterile or agree to use, during the period from informed\n             consent until 90 days following Study Completion, 1 of the following approved methods\n             of contraception: a double barrier method (eg, male condom with spermicide, use by\n             female sexual partner of an intrauterine device with spermicide, a female condom with\n             spermicide, contraceptive sponge with spermicide, a diaphragm with spermicide, or use\n             of a cervical cap with spermicide); a sterile sexual partner; a female sexual partner\n             using an intravaginal system (eg,NuvaRing\u00ae); or a partner using an oral, implantable,\n             transdermal, or injectable contraceptives.\n\n          -  Able to comprehend and willing to sign an informed consent form (ICF).\n\n        Exclusion Criteria:\n\n          -  Significant history or clinical manifestation of any significant metabolic/endocrine,\n             allergic, dermatological, hepatic, renal, hematological, pulmonary, immune,\n             cardiovascular, gastrointestinal, genitourinary, neurological, or psychiatric\n             disorder(as determined by the Investigator).\n\n          -  History of significant hypersensitivity, intolerance, or allergy to any drug\n             compound, food, or other substance, unless approved by the Investigator.\n\n          -  History of stomach or intestinal surgery, nephrectomy, cholecystectomy or resection\n             that would potentially alter absorption and/or excretion of orally administered drugs\n             as determined by the investigator (appendectomy and/or hernia repair may be allowed).\n\n          -  History or presence of an abnormal ECG, which, in the Investigator's opinion, is\n             clinically significant.\n\n          -  Diagnosis of alcoholism or drug addiction within 1 year prior to Period 1 Check-in.\n\n          -  Participation in any other investigational drug study in which receipt of an\n             investigational study drug occurred within 5 half-lives or 30 days, whichever is\n             longer prior to informed consent.\n\n          -  Use of any prescription medications or products within 14 days prior to Period 1\n             prior to informed consent.\n\n          -  Use of any over-the-counter (OTC), non-prescription preparations (including vitamins,\n             minerals, and phytotherapeutic, herbal, dietary supplements, or plant derived\n             preparations) within 7 days prior to each study period Check-in.\n\n          -  Use of alcohol-, grapefruit-, Seville orange-, or caffeine-containing foods, juices,\n             or beverages within 72 hours prior to each study period Check-in.\n\n          -  Use of known hepatic or renal clearance altering agents (eg, erythromycin,\n             cimetidine, barbiturates, phenothiazines, or herbal/plant derived preparations such\n             as St. John's Wort, etc.) for a period of 60 days prior to informed consent;\n\n          -  Poor peripheral venous access.\n\n          -  Donation of blood \u2265 250 mL from 30 days prior to informed consent until study\n             completion, inclusive, or of plasma from 2 weeks prior to informed consent until\n             study completion, inclusive.\n\n          -  Receipt of blood products within 2 months prior to Period 1 Check-in;\n\n          -  Blood pressure greater than 140/90 mmHg confirmed by repeat at Screening or at Period\n             1 Check-in.\n\n          -  Any acute or chronic condition that, in the opinion of the Investigator, would limit\n             the subject's ability to complete and/or participate in this clinical study"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02017236", 
            "org_study_id": "2013-504-CH1"
        }, 
        "intervention": {
            "arm_group_label": [
                "Volitinib ,after high fat meal intake ,capsule", 
                "Volitinib,after general diet,capsule"
            ], 
            "description": "600mgVolitinib ,single dose,oral", 
            "intervention_name": "Volitinib", 
            "intervention_type": "Drug", 
            "other_name": "HMPL-504"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Food Effect", 
            "Health subjects"
        ], 
        "lastchanged_date": "December 16, 2013", 
        "location": {
            "contact": {
                "email": "huam@hmplglobal.com", 
                "last_name": "Chen Yu", 
                "phone": "8621-50790088", 
                "phone_ext": "321"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200031"
                }, 
                "name": "Shanghai Xuhui Central Hospital"
            }, 
            "investigator": {
                "last_name": "Chen Yu", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single Center, Open-label, Randomized, Four-Sequence, Four-period Crossover Study to Investigate Food Effect on the Pharmacokinetics of Single Dose of Volitinib in Healthy Subjects", 
        "other_outcome": {
            "description": "Urinal and fecal excretion ratio of Volitnib, renal clearance of Volitinib;Preliminary metabolite profiling of Volitnib in healthy subjects, with preliminary understanding of the clearance mechanism of Volitinib in human", 
            "measure": "Urinal and fecal excretion ratio of Volitnib;renal clearance of Volitinib", 
            "safety_issue": "Yes", 
            "time_frame": "duriation the first day to the third day after every drug administration"
        }, 
        "overall_contact": {
            "email": "huam@hmplglobal.com", 
            "last_name": "Hua Mu, PhD. MD", 
            "phone": "8621-50790088", 
            "phone_ext": "321"
        }, 
        "overall_official": {
            "affiliation": "Xuhui Center Hospital", 
            "last_name": "Chen yu", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The following PK parameters will be derived from the plasma concentration-time profile of Volitinib  following administration:Area Under Curve (AUC), both from time zero to time with last observation and from time zero to infinity;;Maximum plasma concentration (Cmax);Time to reach the Cmax (Tmax);Apparent oral Clearance (CL/F);Apparent oral Volume of distribution (Vz/F);Other parameters, such as elimination half-life", 
            "measure": "pharmacokinetics", 
            "safety_issue": "Yes", 
            "time_frame": "1-3days after every drug administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02017236"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "AE(adverse event) will be summarized by type and severity", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "1 day to the 14days after every drug administration"
        }, 
        "source": "Hutchison Medipharma Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hutchison Medipharma Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}